Literature DB >> 26582899

The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis.

Jinkuk Choi1, Jie Gao1, Jaekwang Kim2, Cynthia Hong1, Jungsu Kim3, Peter Tontonoz4.   

Abstract

Apolipoprotein E (ApoE) is an important modifier of Alzheimer's disease (AD) pathogenesis, and its abundance has been linked to the clearance of β-amyloid (Aβ) in the brain. The pathways that control the clearance of ApoE in the brain are incompletely understood. We report that Idol, an E3 ubiquitin ligase that targets the low-density lipoprotein receptor (LDLR) for degradation, is a critical determinant of brain ApoE metabolism and Aβ plaque biogenesis. Previous work has shown that Idol contributes minimally to the regulation of hepatic LDLR expression in mice. By contrast, we demonstrate that Idol is a primary physiological regulator of LDLR protein in the brain, controlling the clearance of both ApoE-containing high-density lipoprotein (HDL) particles and Aβ. We studied the consequences of loss of Idol expression in a transgenic mouse model of Aβ amyloidosis. Idol deficiency increased brain LDLR, decreased ApoE, decreased soluble and insoluble Aβ, reduced amyloid plaque burden, and ameliorated neuroinflammation. These findings identify Idol as a gatekeeper of LDLR-dependent ApoE and Aβ clearance in the brain and a potential enzyme target for therapeutic intervention in AD.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26582899      PMCID: PMC7153735          DOI: 10.1126/scitranslmed.aad1904

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  58 in total

Review 1.  Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background.

Authors:  M C Irizarry; G W Rebeck; B Cheung; K Bales; S M Paul; D Holzman; B T Hyman
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.

Authors:  R E Pitas; J K Boyles; S H Lee; D Hui; K H Weisgraber
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

3.  ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.

Authors:  James J Donkin; Sophie Stukas; Veronica Hirsch-Reinshagen; Dhananjay Namjoshi; Anna Wilkinson; Sharon May; Jeniffer Chan; Jianjia Fan; Jon Collins; Cheryl L Wellington
Journal:  J Biol Chem       Date:  2010-08-25       Impact factor: 5.157

4.  The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice.

Authors:  John D Fryer; Ronald B Demattos; Lynn M McCormick; Mark A O'Dell; Michael L Spinner; Kelly R Bales; Steven M Paul; Patrick M Sullivan; Maia Parsadanian; Guojun Bu; David M Holtzman
Journal:  J Biol Chem       Date:  2005-05-11       Impact factor: 5.157

5.  The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice.

Authors:  Cynthia Hong; Stephanie M Marshall; Allison L McDaniel; Mark Graham; Joseph D Layne; Lei Cai; Elena Scotti; Rima Boyadjian; Jason Kim; Brian T Chamberlain; Rajendra K Tangirala; Michael E Jung; Loren Fong; Richard Lee; Stephen G Young; Ryan E Temel; Peter Tontonoz
Journal:  Cell Metab       Date:  2014-11-04       Impact factor: 27.287

6.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.

Authors:  Y Namba; M Tomonaga; H Kawasaki; E Otomo; K Ikeda
Journal:  Brain Res       Date:  1991-02-08       Impact factor: 3.252

7.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.

Authors:  Suzanne E Wahrle; Hong Jiang; Maia Parsadanian; Jungsu Kim; Aimin Li; Amanda Knoten; Sanjay Jain; Veronica Hirsch-Reinshagen; Cheryl L Wellington; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

8.  Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis.

Authors:  Joseph M Castellano; Rashid Deane; Andrew J Gottesdiener; Philip B Verghese; Floy R Stewart; Tim West; Andrew C Paoletti; Tristan R Kasper; Ronald B DeMattos; Berislav V Zlokovic; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

9.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.

Authors:  Joanna L Jankowsky; Daniel J Fadale; Jeffrey Anderson; Guilian M Xu; Victoria Gonzales; Nancy A Jenkins; Neal G Copeland; Michael K Lee; Linda H Younkin; Steven L Wagner; Steven G Younkin; David R Borchelt
Journal:  Hum Mol Genet       Date:  2003-11-25       Impact factor: 6.150

10.  Mechanisms of amyloid-Beta Peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins.

Authors:  Aaron Y Lai; Joanne McLaurin
Journal:  Int J Alzheimers Dis       Date:  2010-12-20
View more
  14 in total

Review 1.  ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease.

Authors:  Yonghe Li; Jesse R Macyczko; Chia-Chen Liu; Guojun Bu
Journal:  Neurobiol Aging       Date:  2022-03-22       Impact factor: 5.133

2.  IDOL regulates systemic energy balance through control of neuronal VLDLR expression.

Authors:  Stephen D Lee; Christina Priest; Mikael Bjursell; Jie Gao; Douglas V Arneson; In Sook Ahn; Graciel Diamante; J Edward van Veen; Megan G Massa; Anna C Calkin; Jason Kim; Harriet Andersén; Prashant Rajbhandari; Michelle Porritt; Alba Carreras; Andrea Ahnmark; Frank Seeliger; Ingela Maxvall; Pernilla Eliasson; Magnus Althage; Peter Åkerblad; Daniel Lindén; Tracy A Cole; Richard Lee; Helen Boyd; Mohammad Bohlooly-Y; Stephanie M Correa; Xia Yang; Peter Tontonoz; Cynthia Hong
Journal:  Nat Metab       Date:  2019-10-28

Review 3.  Liver X receptors in lipid signalling and membrane homeostasis.

Authors:  Bo Wang; Peter Tontonoz
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

4.  Therapeutic IDOL Reduction Ameliorates Amyloidosis and Improves Cognitive Function in APP/PS1 Mice.

Authors:  Jie Gao; Russell Littman; Graciel Diamante; Xu Xiao; In Sook Ahn; Xia Yang; Tracy A Cole; Peter Tontonoz
Journal:  Mol Cell Biol       Date:  2020-03-30       Impact factor: 4.272

Review 5.  LXR Regulation of Brain Cholesterol: From Development to Disease.

Authors:  Rebecca Courtney; Gary E Landreth
Journal:  Trends Endocrinol Metab       Date:  2016-04-21       Impact factor: 12.015

Review 6.  Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease.

Authors:  Fan Liao; Hyejin Yoon; Jungsu Kim
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

7.  IDOL in metabolic, neurodegenerative and cardiovascular disease.

Authors:  Nienke M van Loon; Patrick C N Rensen; Noam Zelcer
Journal:  Aging (Albany NY)       Date:  2018-10-14       Impact factor: 5.682

8.  Brain proteomics links oxidative stress with metabolic and cellular stress response proteins in behavioural alteration of Alzheimer's disease model rats.

Authors:  Mohammad Azizur Rahman; Shahdat Hossain; Noorlidah Abdullah; Norhaniza Aminudin
Journal:  AIMS Neurosci       Date:  2019-11-15

9.  Idolizing the clearance of Amyloid-β by microglia.

Authors:  Nienke Marlies Van Loon; Noam Zelcer
Journal:  Ann Transl Med       Date:  2016-12

10.  Inactivation of the E3 Ubiquitin Ligase IDOL Attenuates Diet-Induced Obesity and Metabolic Dysfunction in Mice.

Authors:  Nienke M van Loon; Roelof Ottenhoff; Sander Kooijman; Martina Moeton; Saskia Scheij; Reinout L P Roscam Abbing; Marion J J Gijbels; Johannes H M Levels; Vincenzo Sorrentino; Jimmy F P Berbée; Patrick C N Rensen; Noam Zelcer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.